CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 6 incoming connections
- ScaleLevered free cash flow is $18.24M, above the global median of $16.24M
- PositionGross margin is 81.9%, higher than 95% of its Diagnostics & Research peers (median 47%)
- Interpretations7 currently firing — 1 · 6
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
6.04%Above 5Y avg (2.16%)
Annual Rate
CNY 0.70Paid annual
Payout Ratio
250.0%High
Payback Period
16.7 yr
Last Ex-Dividend
May 29, 2026
Screen for this company's dividend patterns
Find other companies where the same dividend readings fire.
High Dividend Payout With FCF And Equity Ratio
→dividend payout intensity
fcf positive 3y
ratio balance equity
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company return capital?
High Dividend Payout With FCF And Equity Ratio
It pays out most of its earnings, on three years of positive free cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.79BCNY1.01B · vs all stocks (USD)
Trailing P/E
33.03xvs Diagnostics & Research peers
Revenue (TTM)
1.37BCNY203.55M · vs all stocks (USD)
Profit Margin
15.48%vs Diagnostics & Research peers
Beta
0.2820xvs all stocks
52-Week Change
-22.73%vs all stocks
Market Capitalization
6.79BCNY1.01B · vs all stocks (USD)
Enterprise Value
7.39BCNY1.10B · vs all stocks (USD)
Trailing P/E
33.03xvs Diagnostics & Research peers
Forward P/E
9.83xvs Diagnostics & Research peers
Price to Sales (TTM)
5.09xvs Diagnostics & Research peers
Price to Book (MRQ)
1.79xvs Diagnostics & Research peers
Enterprise to Revenue
5.39xvs Diagnostics & Research peers
Enterprise to EBITDA
14.13xvs Diagnostics & Research peers
Gross Margin
81.94%vs Diagnostics & Research peers
Profit Margin
15.48%vs Diagnostics & Research peers
Operating Margin
38.28%vs Diagnostics & Research peers
Return on Assets (TTM)
5.26%vs Diagnostics & Research peers
Return on Equity (TTM)
5.25%vs Diagnostics & Research peers
Revenue (TTM)
1.37BCNY203.55M · vs all stocks (USD)
Revenue per Share (TTM)
2.32CNYUpdated Aug 19, 2026Quarterly Revenue Growth
4.70%vs Diagnostics & Research peers
Gross Profit (TTM)
1.09BCNY161.41M · vs all stocks (USD)
EBITDA (TTM)
508.33MCNY75.50M · vs all stocks (USD)
Net Income (TTM)
212.22MCNY31.52M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
26.80%vs Diagnostics & Research peers
Operating Cash Flow (TTM)
589.67MCNY87.58M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
122.80MCNY18.24M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.7000CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
6.04%vs all stocks
5-Year Average Dividend Yield
2.16%vs all stocks
Payout Ratio
250.00%vs Diagnostics & Research peers
Minority Interest (Equity)
-5.16MCNYFY2025 · Dec 31, 2025Revenue
1.36BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
279.92MCNYFY2025 · Dec 31, 2025Gross Profit
1.08BCNYFY2025 · Dec 31, 2025Operating Income
474.78MCNY70.51M · vs all stocks (USD)
Pre-tax Income
236.25MCNYFY2025 · Dec 31, 2025Income Tax Expense
45.71MCNYFY2025 · Dec 31, 2025Net Income
190.54MCNYFY2025 · Dec 31, 2025EBIT
285.70MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
567.53MCNYFY2025 · Dec 31, 2025Research & Development
181.73MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
210.55MCNYFY2025 · Dec 31, 2025Other Operating Expenses
18.52MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
10.44MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
49.44MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.3200CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.3200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
593.36MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
593.36MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
190.54MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-663.11KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
352.16MCNYFY2025 · Dec 31, 2025Free Cash Flow
312.98MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
539.65MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
190.54MCNYFY2025 · Dec 31, 2025Other Non-cash Items
50.33MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
100.07MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
11.23MCNYFY2025 · Dec 31, 2025Capital Expenditures
-39.18MCNYFY2025 · Dec 31, 2025Net Acquisitions
0.00CNYFY2025 · Dec 31, 2025Purchase of Investments
-459.71MCNYFY2025 · Dec 31, 2025Sale of Investments
73.57MCNYFY2025 · Dec 31, 2025Other Investing Activity
-50.00MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-475.32MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.32MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-127.42MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-537.14MCNYFY2025 · Dec 31, 2025Other Financing Charges
-14.56MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-677.80MCNYFY2025 · Dec 31, 2025Shares Outstanding
586.31MSharesUpdated Aug 19, 2026Float Shares
217.82MSharesUpdated Aug 19, 2026% Held by Insiders
64.61%vs all stocks
% Held by Institutions
2.69%vs all stocks
Total Cash (MRQ)
673.35MCNY100.01M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.15CNYUpdated Aug 19, 2026Total Debt (MRQ)
1.09BCNY161.88M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2805xvs Diagnostics & Research peers
Current Ratio (MRQ)
12.18xvs Diagnostics & Research peers
Book Value per Share (MRQ)
6.63CNYUpdated Aug 19, 2026Total Assets
5.05BCNY750.39M · vs all stocks (USD)
Total Current Assets
2.20BCNYFY2025 · Dec 31, 2025Total Liabilities
1.27BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.85BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.10BCNYFY2025 · Dec 31, 2025Total Current Liabilities
171.32MCNYFY2025 · Dec 31, 2025Cash
539.63MCNYFY2025 · Dec 31, 2025Cash Equivalents
14.35KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
539.65MCNYFY2025 · Dec 31, 2025Accounts Receivable
1.01BCNYFY2025 · Dec 31, 2025Inventory
187.11MCNYFY2025 · Dec 31, 2025Accounts Payable
51.93MCNYFY2025 · Dec 31, 2025Short-term Debt
9.75MCNYFY2025 · Dec 31, 2025Other Current Liabilities
13.65MCNYFY2025 · Dec 31, 2025Long-term Debt
1.07BCNYFY2025 · Dec 31, 2025Common Stock (Book)
586.31MCNYFY2025 · Dec 31, 2025Retained Earnings
2.47BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.78BCNY561.83M · vs all stocks (USD)
Treasury Stock
57.84MCNYFY2025 · Dec 31, 202552-Week Low
10.52CNYUpdated Aug 19, 202652-Week High
16.05CNYUpdated Aug 19, 202652-Week Change
-22.73%vs all stocks
Beta
0.2820xvs all stocks
50-Day MA
11.48CNYUpdated Aug 19, 2026200-Day MA
12.62CNYUpdated Aug 19, 2026Avg 10-Day Volume
5.37MSharesUpdated Aug 19, 2026Avg 30-Day Volume
5.14MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.3600CNYUpdated Aug 19, 20266 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Retained Earnings Heavy With Elevated Payout
Profits kept in the business fund much of what it owns, and it now pays out most of what it earns.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
How is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 81.9%, higher than 95% of its Diagnostics & Research peers (median 47%)Significant
Gross margin: 0.82Industry median: 0.47Industry P95: 0.80Peers compared: 28.00
Operating margin is 38.3%, higher than 95% of its Diagnostics & Research peers (median 9.9%)Significant
Operating margin: 0.38Industry median: 0.10Industry P95: 0.35Peers compared: 28.00
Current ratio is 12.18×, higher than 95% of its Diagnostics & Research peers (median 2.76×)Significant
Current ratio: 12.18Industry median: 2.76Industry P95: 11.87Peers compared: 28.00
Financial Health
Altman Z-Score 4.83: safe zoneNotable
Altman Z-Score: 4.83
Supply Chain
Midstream position: 6 outgoing, 6 incoming connectionsNotable
Outgoing: 6.00Incoming: 6.00
High connectivity hub: 12 industry connectionsNotable
Total Connections: 12.00
Scale
Levered free cash flow is $18.24M, above the global median of $16.24MNotable
Levered free cash flow (USD): 18,238,235.801Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Kempower Oyj
Tier 1ProductionThroughput-Bound ConversionFlowRule
Voltalia SA
Tier 1ProductionThroughput-Bound ConversionFlowRule
State Power Rixin Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Create Technology & Science Co. Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRisk
Shenzhen United Winners Laser Equipment Co. Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRisk
Shenma Industry Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Smarter Microelectronics Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Reliance Power Ltd
Tier 1ProductionThroughput-Bound ConversionRuleFlow
ITM Power Plc
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Qingdao Gaoce Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Imeik Technology Development Co., Ltd.
6 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsHigh Dividend Payout With FCF And Equity RatioHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedRetained Earnings Heavy With Elevated PayoutThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Goneo Group Co., Ltd.
6 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsHigh Dividend Payout With FCF And Equity RatioHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedRetained Earnings Heavy With Elevated PayoutThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Chengdu Fusen Noble-House Co., Ltd.
6 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsHigh Dividend Payout With FCF And Equity RatioHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedRetained Earnings Heavy With Elevated PayoutThree Margin Ratios Elevated Across Gross, Operating, And Net Levels